Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00932282 · ClinicalTrials.gov registry record · Phase 1
Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy
A Phase 1 study of Peanut Hypersensitivity, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT00932282 is a Phase 1 study of Peanut Hypersensitivity that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 13 participants, below the 49-participant average among 3 other Peanut Hypersensitivity trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00932282, a Phase 1 study of Peanut Hypersensitivity, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether the addition of anti-IgE treatment will make peanut oral immunotherapy safer, more tolerable, and more effective in treating peanut allergy.
Conditions Studied
Interventions
- DRUG Omalizumab
- DRUG Peanut Oral Immunotherapy
Study Locations (1)
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2009-07 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00932282
The ClinicalTrials.gov registry entry for NCT00932282 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 49-participant average among 3 other Peanut Hypersensitivity trials with a reported enrollment target (73% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peanut Hypersensitivity appearing as the primary indexed condition, and to 2 interventions - of which Omalizumab is the first listed.
NCT00932282 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00932282 about?
NCT00932282 is a clinical study titled "Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy". The purpose of this study is to determine whether the addition of anti-IgE treatment will make peanut oral immunotherapy safer, more tolerable, and more effective in treating peanut allergy.
What is the current status of trial NCT00932282?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2009-07. Estimated completion is 2015-08.
What conditions does trial NCT00932282 study?
This clinical trial studies the following conditions: Peanut Hypersensitivity.
What interventions are being tested in trial NCT00932282?
The interventions under investigation include: Omalizumab (DRUG), Peanut Oral Immunotherapy (DRUG).
Who is sponsoring clinical trial NCT00932282?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00932282 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peanut Hypersensitivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy
COMPLETED · Phase 1
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
-
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.